All Boards >> Irritable Bowel Syndrome Research Library

View all threads Posts     Flat       Threaded

Pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | (show all)
Extraintestinal symptoms in IBS and IBD new
      #14125 - 07/15/03 06:21 PM
HeatherAdministrator

Reged: 12/09/02
Posts: 7799
Loc: Seattle, WA

Dig Dis Sci. 2003 Apr;48(4):743-9.

Extraintestinal symptoms in irritable bowel syndrome and inflammatory bowel diseases: nature, severity, and relationship to gastrointestinal symptoms.

Zimmerman J.

The Gastroenterology Unit, Hadassah University Hospital, Jerusalem, Israel 91 120.

Patients suffering from the irritable bowel syndrome (IBS) tend to have extraintestinal symptoms. The purposes of this study were to compare the nature and severity of these symptoms in IBS patients in relation to patients with inflammatory bowel disease (IBD) and to nonpatients and to clarify the relationship between intestinal and extraintestinal symptoms. A consecutive group of male patients and a control group of age-matched male subjects were studied. Symptoms were graded for severity using a validated, self-administered inventory. There were 53 IBS patients, 55 IBD patients (32 Crohn's disease), and 56 controls. IBS patients scored significantly higher than IBD patients on constipation, dyspepsia, and reflux scales. Musculoskeletal symptoms, neurasthenia, and sleep scores were similar in IBS and IBD patients, and both groups scored significantly higher than the controls. The scores of urinary, thoracic, and oral symptoms were similar in IBD patients and in controls. However, IBS patients scored significantly higher than both groups on all these scales. Reflux symptoms were the most powerful predictors of extraintestinal symptoms, both in IBS and in IBD. Diarrhea was predictive of extraintestinal symptoms only in IBD. In conclusion, IBS patients experienced extraintestinal symptoms to the same extent, or even more than patients with IBD. However, the relationship between intestinal and extraintestinal symptoms differed in the two conditions.

PMID: 12741465 [PubMed - indexed for MEDLINE]
web page

--------------------
Heather is the Administrator of the IBS Message Boards. She is the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Print     Remind Me     Notify Moderator    

Treatment of the irritable bowel syndrome. new
      #14151 - 07/15/03 11:02 PM
HeatherAdministrator

Reged: 12/09/02
Posts: 7799
Loc: Seattle, WA

Gastroenterol Clin North Am. 1991 Jun;20(2):325-33.

Treatment of the irritable bowel syndrome.

Friedman G.

Department of Medicine, Mt. Sinai School of Medicine, New York, New York.

Individualization of treatment for patients with IBS is predicated on a thorough analysis of the patient's symptoms, consideration of the reasons for seeking health care, evaluation of symptom-precipitating factors, elimination of confounding features, and the absolute knowledge of the absence of organic illness. Collecting and codifying appropriate historical data allow the physician to educate the patient with respect to the origin of his symptoms, and to enlist the patient as a partner in his future health care. There is no single, universally accepted therapeutic agent available for the treatment of the IBS patient. As a result, treatment is directed at reducing the frequency and intensity of triggering factors as well as ameliorating the symptoms when they arise. Symptoms evoked by psychologic factors may be effectively reduced by psychotherapy or hypnotherapy. Situational anxiety may be treated for brief periods by using antianxiety agents such as diazepam, chlordiazepoxide, buspirone, or similar agents. Depressive reactions may be reduced with suitable doses of antidepressant agents such as amitriptyline. Smooth muscle hyperreactivity may be dulled with small amounts of selected anticholinergics, which are usually most effective in reducing meal-induced discomfort. Peppermint oil may be of additional benefit. Gas-related symptoms require elimination of contributory dietary factors, such as lactose-containing foods, sorbitol, or fructose, as well as certain oligosaccharides. Simethecone, charcoal, or beanase may be helpful. Functional constipation is best treated with graded doses of insoluble or soluble fiber. Diarrheal episodes may be reduced with either loperamide or diphenoxylate. Careful, continued follow-up assessment of therapeutic endeavors, a sincere interest in the patient's concerns, and surveillance for intercurrent organic illness are the cornerstones of complete ongoing care.

Publication Types:
Review Review, Tutorial

PMID: 2066156 [PubMed - indexed for MEDLINE]

web page



--------------------
Heather is the Administrator of the IBS Message Boards. She is the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Print     Remind Me     Notify Moderator    

Antibiotics increase functional abdominal symptoms. new
      #14325 - 07/18/03 11:41 AM
HeatherAdministrator

Reged: 12/09/02
Posts: 7799
Loc: Seattle, WA

Am J Gastroenterol. 2002 Jan;97(1):104-8.

Antibiotics increase functional abdominal symptoms.

Maxwell PR, Rink E, Kumar D, Mendall MA.

Department of General Practice and Primary Care, St George's Hospital Medical School, London, United Kingdom.

OBJECTIVES: Data suggest that subjects with irritable bowel syndrome are more likely to report a recent course of antibiotics. This study tests the hypothesis that a course of antibiotics is a risk factor for an increase in the number of functional bowel complaints over a 4-month period in a general population sample. METHODS: We initiated a prospective case-control study in three general practices in South London. Consecutive patients aged 16-49 attending their general practitioner with non-GI complaints and given a prescription for antibiotics were invited to participate. Comparison subjects who had not had antibiotics for 1 yr were identified from the practice records by age group, gender, and previous general practitioner visits. Fifty-eight antibiotic and 65 control patients agreed to participate. Questionnaires covering demographic, GI, and psychological data were sent at recruitment and at 4 months. Seventy-four percent of subjects completed the study. The number of symptoms at follow-up compared to that at recruitment. RESULTS: Twenty of 42 antibiotic subjects (48%) versus 11/49 control subjects (22%) demonstrated one or more additional functional bowel symptoms at 4 months (unadjusted odds ratio = 3.14 [1.27-7.75]) (chi2 = 6.4, p = 0.01). Ten of 42 antibiotic subjects (24%) versus 3/49 control subjects (6%) demonstrated two or more additional functional bowel symptoms at 4 months (unadjusted odds ratio = 4.79 [1.22-18.80]) (chi2 = 5.8, p = 0.02). CONCLUSIONS: Functional bowel symptoms come and go, but subjects who are given a course of antibiotics are more than three times as likely to report more bowel symptoms 4 months later than controls.

PMID: 11808932 [PubMed - indexed for MEDLINE]
web page

--------------------
Heather is the Administrator of the IBS Message Boards. She is the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Print     Remind Me     Notify Moderator    

Eradication of small intestinal bacterial overgrowth reduces symptoms of IBS new
      #14329 - 07/18/03 11:44 AM
HeatherAdministrator

Reged: 12/09/02
Posts: 7799
Loc: Seattle, WA

Am J Gastroenterol. 2000 Dec;95(12):3503-6.

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.

Pimentel M, Chow EJ, Lin HC.

Department of Medicine, Cedars-Sinai Medical Center, CSMC Burns & Allen Research Institute, and School of Medicine, University of California, Los Angeles, 90048, USA.

OBJECTIVES: Irritable bowel syndrome is the most common gastrointestinal diagnosis. The symptoms of irritable bowel syndrome are similar to those of small intestinal bacterial overgrowth. The purpose of this study was to test whether overgrowth is associated with irritable bowel syndrome and whether treatment of overgrowth reduces their intestinal complaints. METHODS: Two hundred two subjects in a prospective database of subjects referred from the community undergoing a lactulose hydrogen breath test for assessment of overgrowth were Rome I criteria positive for irritable bowel syndrome. They were treated with open label antibiotics after positive breath test. Subjects returning for follow-up breath test to confirm eradication of overgrowth were also assessed. Subjects with inflammatory bowel disease, abdominal surgery, or subjects demonstrating rapid transit were excluded. Baseline and after treatment symptoms were rated on visual analog scales for bloating, diarrhea, abdominal pain, defecation relief, mucous, sensation of incomplete evacuation, straining, and urgency. Subjects were blinded to their breath test results until completion of the questionnaire. RESULTS: Of 202 irritable bowel syndrome patients, 157 (78%) had overgrowth. Of these, 47 had follow-up testing. Twenty-five of 47 follow-up subjects had eradication of small intestinal bacterial overgrowth. Comparison of those that eradicated to those that failed to eradicate revealed an improvement in irritable bowel syndrome symptoms with diarrhea and abdominal pain being statistically significant after Bonferroni correction (p < 0.05). Furthermore, 48% of eradicated subjects no longer met Rome criteria (chi2 = 12.0, p < 0.001). No difference was seen if eradication was not successful. CONCLUSIONS: Small intestinal bacterial overgrowth is associated with irritable bowel syndrome. Eradication of the overgrowth eliminates irritable bowel syndrome by study criteria in 48% of subjects.

PMID: 11151884 [PubMed - indexed for MEDLINE]
web page

--------------------
Heather is the Administrator of the IBS Message Boards. She is the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Print     Remind Me     Notify Moderator    

Diagnosis of irritable bowel syndrome. new
      #14332 - 07/18/03 11:54 AM
HeatherAdministrator

Reged: 12/09/02
Posts: 7799
Loc: Seattle, WA

ogy. 2002 May;122(6):1701-14.

Diagnosis of irritable bowel syndrome.

Olden KW.

Department of Medicine, Division of Gastroenterology, Mayo Clinic Scottsdale, 13400 E. Shea Boulevard, Scottsdale, Arizona 85259, USA. olden.kevin@mayo.edu

Irritable bowel syndrome (IBS) is the most common disorder seen in gastroenterology practice. It is also a large component of primary care practices. Although the classic IBS symptoms of lower abdominal pain, bloating, and alteration of bowel habits is easily recognizable to most physicians, diagnosing IBS remains a challenge. This is in part caused by the absence of anatomic or physiologic markers. For this reason, the diagnosis of IBS currently needs to be made on clinical grounds. A number of symptom-based diagnostic criteria have been proposed over the last 15 years. The most recent of these, the Rome II criteria, seem to show reasonable sensitivity and specificity in diagnosing IBS. However, the role of the Rome II criteria in clinical practice remains ill defined. A review of the literature shows that, in patients with no alarm symptoms, the Rome criteria have a positive predictive value of approximately 98%, and that additional diagnostic tests have a yield of 2% or less. Diagnostic evaluation should also include a psychosocial assessment specifically addressing any history of sexual or physical abuse because these issues significantly influence management strategies and treatment success.

Publication Types:
Review
Review, Tutorial

PMID: 12016433 [PubMed - indexed for MEDLINE]
web page

--------------------
Heather is the Administrator of the IBS Message Boards. She is the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Print     Remind Me     Notify Moderator    

Bacterial Overgrowth in IBS new
      #14337 - 07/18/03 12:15 PM
HeatherAdministrator

Reged: 12/09/02
Posts: 7799
Loc: Seattle, WA

BACTERIAL OVERGROWTH IN IBS
Douglas A. Drossman, MD
Center Co-Director

In the December issue of the American Journal of Gastroenterology, a relatively small study peaked the interest of news reporters, primarily because it was believed that "the answer" to understanding and treating IBS was at hand. The article entitled "Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of IBS" by M. Pimental, E.J. Chow and H.C. Lin found that 78% of 157 patients referred to their center for breath hydrogen testing for bacterial overgrowth were found to have bacterial overgrowth. Furthermore, over half (25 of 47) of the patients who were treated with antibiotics and came back for later testing had a reduction in their IBS symptoms.

We recognize bacterial overgrowth in the small intestine to be associated with symptoms similar to IBS (bloating, abdominal pain and diarrhea), and those who have the proper equipment (as we do at our Center), can perform this test easily and painlessly. The subject drinks about a quart of a sugar solution (e.g., lactose) that is not absorbed in the small intestine, so it usually passes to the large intestine where it is broken down by bacteria and gas is produced as a waste product which is sent to the lung as hydrogen. Because bacteria are found in very high concentration in the large, but not the small intestine, the production of the gas occurs late (after 90 minutes). So when more than the usual number of bacteria is found in the small intestine (bacterial overgrowth), they will digest the lactose sooner, producing an earlier excretion of hydrogen in the lungs. In addition, the patients may also develop symptoms of gas, bloating and diarrhea. When bacterial overgrowth is diagnosed, it can be treated with antibiotics and this will reduce the symptoms, at least. What was different about this article was that the frequency of bacterial overgrowth in this study was far higher than clinicians and investigators had previously found.

The information reported was met with a great deal of enthusiasm. To quote Reuter's press on 12/13:"Los Angeles, CA - Irritable bowel syndrome, a chronic condition believed to plague 20% of the adult population…..May be caused by too much bacteria in the small intestine, researches said Wednesday. ' It was the first time a potential cause for the disease has been identified and could lead to a radical shift in treatment', according to the lead investigator of the study. 'This is really exciting because it points to the cause of the disease. Treatments for IBS to this point have been directed at symptoms, not any cause' said Dr. Mark Pimental…..". This kind of information was communicated in newspapers, TV and the Internet, and Drs. Whitehead and I were asked to comment as to whether this was indeed a major breakthrough in research.

Before getting too encouraged, it would help to identify some of the limitations of this study before drawing any conclusions:

Patients were referred to the medical center specifically for breath hydrogen testing after being evaluated by physicians who suspected this diagnosis. This would tend to skew the proportion of persons with positive studies, simply because the doctors have already suspected the diagnosis. So the 78% figure may be higher than might occur in a better designed study.


This is not a placebo-controlled double-blinded study. In well-designed studies, a proportion of subjects receive a placebo, so the investigators can compare the benefits of those on the active treatment to those on placebo. In addition, usually, neither the study subjects nor the investigators know who is getting the active drug or placebo. But when there is no placebo, then all patients (and investigators) will know they are receiving the active treatment (i.e., the antibiotics), and they may do better ("placebo effect") because they expect to do better. So the level of improvement here might be higher than if the study subjects did not know which treatment they were getting.


Although 157 patients were tested for bacterial overgrowth, less than 1/3 were actually tested with regard to benefits from treatment. It is unclear why so few patients came back. Were the ones who didn't come back doing better or worse? Preferably, efforts need to be made to study all patients in order to know if the results are valid.


This was a "convenience study". It appears that the authors went back in the clinical records to report their results rather than design a prospective study where patients follow a specific protocol. For example, at least four different antibiotics were used by different physicians. So it is unknown whether one antibiotic might be better than another, and these kinds of differences in how the study is conducted will interfere with the conclusions that can be drawn from the study.
In summary, I believe that while the findings being reported are not a major breakthrough, they should increase awareness of one disorder that can mimic or worsen IBS. In our experience at the UNC Center for Functional GI and Motility Disorders, the frequency is much lower (maybe <10%) of people who come to us with IBS. But when we suspect bacterial overgrowth based on certain clinical features, we then test for it, and of course, there is a greater chance the test will be positive. In those cases we treat, and many (but not all) will respond; however, the symptoms may return.

Patients with IBS should consider a diagnosis of bacterial overgrowth if you have diarrhea, abdominal swelling and increased gas production within 30-45 minutes after eating. But these symptoms are also quite typical just for IBS. Your physician will work with you to determine if breath testing for bacterial overgrowth may be helpful.

UNC Center for Functional GI & Motility Disorders
Bioinformatics Building, CB #7080
Chapel Hill, NC 27599-7080
(919) 843-0821 (phone)

web page

--------------------
Heather is the Administrator of the IBS Message Boards. She is the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Print     Remind Me     Notify Moderator    

UCLA/CURE Neuroenteric Disease Program Newsletter new
      #14676 - 07/23/03 10:38 AM
HeatherAdministrator

Reged: 12/09/02
Posts: 7799
Loc: Seattle, WA

UCLA/CURE Neuroenteric Disease Program Newsletter

The Inside Trak

Our Newsletter "The Inside Trak" is a semiannual publication aimed at patients suffering from IBS and other chronic disorders of the gastrointestinal tract. The articles appearing in the newsletter are written by the members of the Neuroenteric Disease Program and deal with a wide range of issues which we feel our patients are interested in. In particular, we are aiming to update patients on new developments in research, drug development and ongoing clinical studies. Get newsletter issues here:
web page

--------------------
Heather is the Administrator of the IBS Message Boards. She is the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Print     Remind Me     Notify Moderator    

Distinctive features of postinfective irritable bowel syndrome new
      #15251 - 07/28/03 03:18 PM
HeatherAdministrator

Reged: 12/09/02
Posts: 7799
Loc: Seattle, WA

Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome

Simon P. Dunlop M.Sc. a , David Jenkins M.D. b and Robin C. Spiller M.D.



--------------------------------------------------------------------------------


Abstract

Objective


Irritable bowel syndrome after gastroenteritis is well recognized. Our aim was to determine whether postinfective IBS (PI-IBS) has histological or clinical features that are distinct from those of IBS patients with no history of preceding infection.


Methods


A total of 75 consecutive IBS outpatients and 36 healthy control subjects completed a questionnaire detailing symptoms, mode of onset, and previous psychiatric history. All underwent a full diagnostic workup including rectal biopsy, which included immunostaining and quantification for lamina propria or intraepithelial T lymphocytes, serotonin-containing enterochromaffin (EC), and mast cells. Patients were divided according to onset of symptoms into PI-IBS (n = 23) or non–PI-IBS (n = 52) patients.


Results


Diarrhea predominance occurred more frequently in PI-IBS (70%) than in non–PI-IBS (42%) patients (p = 0.03). A history of previous treatment for anxiety or depression was present in 26% of PI-IBS patients compared to 54% of non–PI-IBS (p = 0.02). Biopsy results for all patients were normal using conventional criteria; however, quantification revealed that PI-IBS showed increased EC cells compared to those of non–PI-IBS patients (p = 0.017) and controls (p = 0.02). Lamina propria T lymphocytes were increased in PI-IBS (p = 0.026) and non–PI-IBS (p = 0.011) patients compared to controls. Mast cells were increased in non–PI-IBS patients (p = 0.054) compared to controls.


Conclusions


Individuals with PI-IBS are a clinically distinct subgroup characterized by diarrheal symptoms, less psychiatric illness, and increased serotonin-containing EC cells compared to those with non–PI-IBS.

web page


--------------------
Heather is the Administrator of the IBS Message Boards. She is the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Print     Remind Me     Notify Moderator    

Cognitive-behavioral therapy versus education and desipramine versus placebo for IBS new
      #17068 - 08/12/03 12:54 PM
HeatherAdministrator

Reged: 12/09/02
Posts: 7799
Loc: Seattle, WA

Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders

Gastroenterology July 2003 • Volume 125 • Number 1



Background & aims: Studies of antidepressants and psychological treatments in functional bowel disorders (FBD) are methodologically limited. The aim of this study was to assess the clinical efficacy and safety of cognitive-behavioral therapy (CBT) against education (EDU) and desipramine (DES) against placebo (PLA) in female patients with moderate to severe FBD (irritable bowel syndrome, functional abdominal pain, painful constipation, and unspecified FBD). We also evaluated the amenability of clinically meaningful subgroups to these treatments.

Methods: This randomized, comparator-controlled, multicenter trial enrolled 431 adults from the University of North Carolina and the University of Toronto with moderate to severe symptoms of FBD. Participants received psychological (CBT vs. EDU) or antidepressant (DES vs. PLA) treatment for 12 weeks. Clinical, physiologic, and psychosocial assessments were performed before and at the end of treatment.

Results: The intention-to-treat analysis showed CBT as significantly more effective than EDU (P = 0.0001; responder rate, 70% CBT vs. 37% EDU; number needed to treat [NNT ], 3.1). DES did not show significant benefit over PLA in the intention-to-treat analysis (P = 0.16; responder rate, 60% DES vs. 47% PLA; NNT, 8.1) but did show a statistically significant benefit in the per-protocol analysis (P = 0.01; responder rate, 73% DES vs. 49% PLA; NNT, 5.2), especially when participants with nondetectable blood levels of DES were excluded (P = 0.002). Improvement was best gauged by satisfaction with treatment. Subgroup analyses showed that DES was beneficial over PLA for moderate more than severe symptoms, abuse history, no depression, and diarrhea-predominant symptoms; CBT was beneficial over EDU for all subgroups except for depression.

Conclusions: For female patients with moderate to severe FBD, CBT is effective and DES may be effective when taken adequately. Certain clinical subgroups are more or less amenable to these treatments.

*UNC Center for Functional GI and Motility Disorders, Division of Digestive Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
‡Center for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
§Division of Gastroenterology, University of Toronto, Toronto, Ontario, Canada
''GlaxoSmithKline, Research Triangle Park, North Carolina, USA
¶Global Outcomes Research, Pharmacia Corp., Kalamazoo, Michigan, USA
#Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Supported by a research grant from the National Institutes of Health (RO1-DK49334).

1This study was registered with ClinicalTrials.gov (trial registry no. NCT00006157).
Submitted December 6, 2002.

Accepted on April 3, 2003.

Copyright © 2003 by American Gastroenterological Association

doi:10.1016/S0016-5085(03)00669-3

web page



--------------------
Heather is the Administrator of the IBS Message Boards. She is the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Print     Remind Me     Notify Moderator    

Do published guidelines for evaluation of IBS reflect practice? new
      #19119 - 08/30/03 02:40 PM
HeatherAdministrator

Reged: 12/09/02
Posts: 7799
Loc: Seattle, WA

Do published guidelines for evaluation of Irritable Bowel Syndrome reflect practice?

BMC Gastroenterol. 2001; 1 (1): 11

Barbara P. Yawn, ,1 Eva Lydick, ,2 G Richard. Locke,3 Peter C. Wollan,1 Susan L. Bertram,1 and Margary J. Kurland1

1Department of Research, Olmsted Medical Center, Rochester, Minnesota, USA 2SmithKline Beecham Pharmaceuticals, Division of Epidemiology, Collegeville, Pennsylvania, USA 3Gastroenterology Outcomes Research Unit, Mayo Clinic, Rochester, Minnesota, USA

Received July 25, 2001; Accepted October 26, 2001; Published October 26, 2001.

Background
The only US guidelines listed in the National Guideline Warehouse for the diagnosis of Irritable Bowel Syndrome (IBS) are the expert opinion guidelines published by The American Gastroenterology Association. Although the listed target audience of these guidelines includes family physicians and general internists, the care recommended in the guidelines has not been compared to actual primary care practice. This study was designed to compare expert opinion guidelines with the actual primary care provided and to assess outcomes in the 3 years following the IBS diagnosis.

Methods
This is a retrospective medical record review study using a random sample of incident IBS cases from all Olmsted County, Minnesota providers diagnosed between January 1, 1993 and December 31, 1995. Data was collected on all care and testing provided to the subjects as well as 3-year outcomes related to the IBS diagnosis.

Results
Of the 149 IBS patients, 99 were women and the mean age was 47.6 years. No patient had all of the diagnostic tests recommended in the guidelines. 42% had the basic blood tests of CBC and a chemistry panel. Sedimentation rate (2%) and serum thyroxine level (3%) were uncommon. Colon imaging studies were done in 41% including 74% of those over the age of 50. In the 3 years following the diagnosis, only one person had a change in diagnosis and no diagnoses of gastro-intestinal malignancies were made in the cohort.

Conclusions
Primary care practice based diagnostic evaluations for IBS differ significantly from the specialty expert opinion-based guidelines. Implementation of the specialty guidelines in primary care practice would increase utilization with apparent limited improvement in diagnostic outcomes.


Irritable bowel syndrome is a gastro-intestinal (GI) disorder of unknown etiology often described as a functional bowel problem. [1-3] The diagnosis of IBS rests on the occurrence of a set of symptoms and the exclusion of other GI pathology. [4-7] The only published US guidelines for evaluation of patients with possible IBS have been developed by the American Gastroenterological Association (AGA).[3] Due to the lack of higher levels of evidence, the guidelines are based on expert opinion and are likely to reflect the clinical experience of these specialists with the small percent (6 to 8%)[8] of all IBS patients seen by gastroenterologists in the US. [9] Little has been written about the potential implications of implementing the only currently available IBS diagnostic guidelines[10] or how the guidelines compare to existing community practice.

Using a community population-based sample of subjects with an incident diagnosis of IBS, we reviewed the GI-related health care utilization and diagnostic evaluations completed around the time of first (incident) IBS diagnosis and compared those evaluations to the AGA guidelines for the diagnosis of IBS. In addition, we evaluated the utilization implications of implementing the AGA guidelines in this patient population. The purpose of the study is not to validate the guidelines but to see how they compare to current primary care practice and to understand the potential implications of full guideline implementation.


Setting
Olmsted County is a metropolitan statistical area (MSA) of 135,000 people 90 miles south of Minneapolis, Minnesota. The population is estimated to be 92 percent white non-Hispanic. [11] Olmsted County has local resources for primary, and specialty care. Previous studies estimate that over 98 percent of all Olmsted County residents' health care is delivered within Olmsted County [11] by the Mayo Medical Center (MMC), the Olmsted Medical Center (OMC) or the single solo practice family physician's office in Rochester.

Data Collection
The cohort was identified using the database of the Rochester Epidemiology Project (REP)[11,12] that collects all diagnoses made within all Olmsted County medical facilities and links all people in Olmsted County to all sources of health care they use. All people with a diagnosis of functional or irritable bowel syndrome (564.1) or spastic colon – psychogenic (306.4) during 1993–1995 were identified from the database. Broad criteria were used for the search to increase sensitivity at the risk of reducing specificity. This type of search strategy was possible since final subject selection relied on medical record review rather than only administrative data. [13] The initial search identified 1245 potential cases (a combination of incident and prevalent cases) of which 36 (2.9%) had previously refused general record review research authorization and thus could not be included in the study according to Minnesota statute.[14] The goal was to identify 150 subjects for in-depth review using data from all sources of medical care each individual has used within the county. The sample size was selected based on the desire to have a sufficient sample to provide estimates of compliance with individual elements of the guidelines with confidence intervals of +/- 5% for those tests with very high and very low compliance and +/-8% for those near 50% compliance. This is a descriptive study and therefore no other types of sample size calculations were made.

The 1245 people identified by the initial search of the REP database, were put into a random order and the medical records of potential subjects' were screened until the final cohort of 150 patients who met the inclusion criteria were identified. A total of 416 potential IBS subjects were screened to identify the final incident cohort of 150 subjects who had lived in Olmsted County for at least 3 years and had no previous diagnoses of IBS listed in any medical records in the county. The minimum of 3 years of residency within Olmsted County was used to improve the likelihood that review of the complete available medical records would identify prevalent rather than incident cases of IBS. The assurance that patients represented an incident diagnosis of IBS was especially important in this study comparing diagnostic evaluations completed to the recommended guidelines for initial evaluation. Potential subjects from the group of 416 were excluded during screening primarily for 1 of 3 reasons: they were prevalent rather than incident cases of IBS (n = 67), no actual diagnosis of IBS was documented in any of the subject's medical records (n = 41) or they had been an Olmsted County resident for < 3 years (n = 93). Another 65 people had a group of miscellaneous reasons for exclusion including incident diagnosis date outside the window of this study, age < 16 at diagnosis, and missing records.

All medical records of the 150 subjects in the final cohort (those meeting the eligibility criteria) were reviewed in detail to abstract data on demographic characteristics, visits for gastro-intestinal or abdominal problems, and non-GI symptom-related visits from 10 years before the first IBS diagnosis to 3 years after. GI symptom-related visits were those in which any symptom, sign or complaint referable to the GI tract was recorded. This included such complaints as diarrhea, abdominal pain, constipation, change in stool habits, and vomiting. All other visits were considered non-GI related. Information on the presenting complaint, specialty of physician seen, tests ordered and site of the visit (emergency department, office, or hospital) was recorded. Data collection began at the earliest visit that occurred 10 years or less before the incident IBS diagnosis. Long term data were available for most patients (mean = 7.3 years, median 7 years) and were used to assure that there was no previous diagnosis of IBS. The data of most interest for this comparison of diagnostic evaluations completed and the testing recommended in the guidelines were visits in 2 years before the diagnosis of IBS. Diagnostic outcomes were assessed during the 3 years after the incident diagnosis. These data were present in 100% of subjects.

Data analysis
One subject revoked general research authorization (required by Minnesota statute) during data analysis and thus the analysis was completed for the remaining 149 subjects. Descriptive information is presented as summary statistics.

Health care utilization was stratified into 2 major time periods: a) the 60 days surrounding the incident IBS diagnosis (30 days before to 30 days after) called the immediate diagnostic period; and b) the 2 years prior to the diagnosis, excluding the 30 days before termed the extended diagnostic period. For referral to a GI specialist we also included the 1 year after the diagnosis since referral for non-urgent conditions may take a considerable period of time. The designation of the 60-day "diagnostic period" was based on the clinical judgement of the authors and was felt to reflect the usual time required to complete a diagnostic evaluation. The percent of subjects using each of the recommended services was calculated for the diagnostic period and then for the extended immediate diagnostic period (included the 2 year period prior to the incident diagnosis). The extended window of time was important for such tests as colonoscopy that may not be repeated within 2 years of a normal examination.

Comparisons of test utilization between age groups, genders and those who did and did not have a gastroenterologist involved in their care were made using the Wilcoxon rank-sum test. Chi-square tests were used to compare frequencies of events.

The potential impact of fully implementing the AGA guidelines (Table 1) was assessed. The additional tests that would be needed for full implementation was calculated by subtracting the tests provided in this study from tests that would need to be completed if all subjects' evaluations met the guidelines. Diagnostic outcomes (e.g. changes in diagnoses from IBS to another GI disease in the 3 years following first IBS diagnosis) is reported as a single percent of total diagnosis.

This study was approved by the Olmsted Medical Center and the Mayo Medical Center Institutional Review Boards. The funding agency had no role in study design or right of approval of manuscripts submitted for publication. The author who worked for the funding agency was one of the epidemiologist members of the design team and reviewed the final draft of the manuscript.

Two thirds of the 149 subjects (n = 99) were women. The mean age of the subjects at the time of diagnosis was 47.6 years (s.d. 17.8 years and range 16 to 91 years) and was the same for men and women. Most of the IBS diagnoses (94%) were made by family physicians and general internists with 13% of subjects seeing a gastroenterologist at any time in the period 2 years before to 1 year after the diagnosis.

Table 2 summarizes the percent of people having each test or group of tests that are recommended for diagnostic evaluation by the AGA guidelines. In this cohort, testing did not vary significantly by sex. Only the completion of some type of colon imaging (flexible sigmoidoscopy, colonoscopy or barium enema) varied by age with 74% (n = 46) of those 50 and older at diagnosis versus 38% (n = 33) of those younger than 50 at diagnosis having one of the tests documented. Since the guidelines were developed by a panel of gastroenterologists, the compliance with the guidelines in those subjects seeing a GI specialist was also calculated (n = 19). All types of colon imaging were more common in those with GI specialty visits [79% (n = 15) versus 50% (n = 64), p > 0.05] but only the increase in flexible sigmoidoscopies reached statistical significance [53%, (n = 10) versus 19%, (n = 25), p < 0.05]. The only other diagnostic tests that were statistically more likely to be completed in those seen by a gastroenterologist were stool testing for ova and parasites [53%, (n = 10) versus 16%, (n = 21), p < 0.05] and fecal occult blood [26%, (n = 5) versus 9% (n = 12), p < 0.05].

The final column of Table 2 reflects the additional number of people (and percent of the subjects) who would require each category of test to comply with the AGA guidelines [3] for diagnosis of IBS.

In those subjects with primarily diarrhea (n = 82), the guidelines suggest a small bowel radiograph and a lactose/dextrose H2 breath test. Twelve subjects (15%) had a small bowel radiograph and none had H2 breath testing. For those with abdominal pain (n = 110) the guidelines recommend a plain film of the abdomen. Thirteen of these patients (12%) had a flat plate.

In the three years after the diagnosis of IBS, only one subject had any change in diagnosis from IBS to another condition related to the symptoms. This 23-year old subject was diagnosed with inflammatory bowel disease approximately one year after the initial IBS diagnosis. No subject was diagnosed with any type of GI-related malignancy and there were no deaths in the cohort.

The evaluation of IBS in this community population-based cohort of primary care patients differed significantly from that recommended by the AGA guidelines [3] for IBS evaluation. The evaluation of GI-related signs and symptoms appeared to be based primarily on history and physical examination with minimal specific testing or imaging of the GI tract. The inclusion of a GI specialist in the subject's care increased but did not guarantee compliance with the AGA guidelines.

The diagnostic guidelines developed and published by the AGA are available in several formats including as part of the guideline warehouse sponsored by the Agency for Health Care Research and Quality (AHRQ) www.guidelines.gov/ibs where they are listed as applicable to family medicine, internal medicine, gastroenterology and primary care. Physicians who are familiar with the medical literature will know that almost all elements of the IBS guideline required expert opinion since little other evidence was available. Unfortunately, the level of evidence used is not clearly stated. [15] Furthermore, the AGA guidelines were developed by a panel limited to gastroenterologist physicians. However, gastroenterologists see only a minority of IBS patients.[8] Over 94% of the subjects in this sample were initially evaluated by family physicians and general internists with only 13% ever seeing a gastroenterologist in the 7 years before or 3 years after the incident IBS diagnosis. Therefore, subspecialty developed guidelines may not be appropriate for the majority of IBS care especially when the guidelines have to be based primarily on opinion which likely reflects only the experience of physicians included in the guideline development panel.

The complete printed position statement that accompanies the original publication of the AGA guidelines does note the potential lack of applicability to primary care patients (> 85% of all IBS patients) stating "...Primary care patients may be different and may be followed with expectant management". [3] However, expectant management is not specified nor are the specific indications for referral to a specialist presented. The position paper also recognizes that "...there is a risk of overdoing the diagnostic evaluation to rule out organic disease". Within the guideline warehouse www.guidelines.gov these modifiers are missing. No data are presented in any format that provide any rationale for extending the AGA guidelines to primary care practice.

The additional testing that would be required to meet the AGA guidelines [3] is extensive (Table 2) and would likely result in significant increases in health care expenditures. Even if the guidelines were applied only to those visiting a gastroenterologist (assumed to be 13% of subjects in our study), additional health care utilization would be required. The anticipated gain in improved diagnostic accuracy appears to be limited since in this cohort only one diagnosis was changed from IBS in the 3 years of follow up after the incident IBS diagnosis.

The value of completing all of the additional testing recommended by the guidelines cannot be completely assessed with this data set. However, the outcome of no new GI malignancies in the three years of follow up of this cohort is comparable to other studies of prognosis in IBS [16] and suggests additional testing would be of limited value in identifying life threatening conditions. The value of the additional testing or referrals on the patient's quality of life or other health conditions is not known and requires additional research. The format of that additional research might be similar to the studies for other guidelines such as the study of the cost implications of implementing guidelines that recommend radiographs for evaluation of low back pain. [17] Such a study for IBS guidelines would need to assess the added value of the extensive work-up recommended by the specialty guidelines in a larger population over a longer period of time and could be compared to the outcomes (including patient satisfaction) of a group assigned to more limited evaluation as completed in this study. It would be important to determine if the additional tests or referrals would identify other diseases, serve to more fully reassure the patient or simply have become what patients and specialist expect to occur with a GI specialty visit. [18]

Failure to comply with one aspect of the guidelines is worth specific mention. While subjects over age 50 were more likely to have colon-imaging studies, 25% of them had no colon imaging studies or assessment of fecal occult blood. This is not consistent with the published evidence based U.S. Preventive Services Task Force (USPSTF) guidelines for routine screening and preventive care related to colon cancer for asymptomatic people 50 years and older and appear to represent missed screening opportunities. [19,20] The addition of a GI specialist in the patient's care increased but did not guarantee compliance with the USPSTF guidelines for screening studies of the colon.

The AGA[3] had little evidence of any higher level than expert opinion on which to base IBS guidelines. The disparity between the testing family physicians and general internists choose to evaluate potential IBS and that recommended in the guidelines highlights the potential impact of using subspecialty experts to define recommended care in a primary care condition with limited research based evidence. If indeed gastroenterologists do see a sicker or otherwise different group of people with IBS than seen by family physicians and general internists then more extensive evaluation by gastroenterologists would be appropriate to consider. If the GI specialty patients are no more likely to have other diseases but are just more likely to be dissatisfied with care and need additional reassurance, more testing may not be the most cost effective solution. Alternative considerations such as group therapy, support groups or additional education may be a better use of resources and time. [21] In this population, the disparity between the care given and that recommended reinforces the value of understanding the full spectrum of disease when developing opinion based guidelines as well as the importance of developing evidence based guidelines as opposed to expert opinion based guidelines whenever possible.

This is a relatively small cohort of primary care patients from a single county. Practices in other communities and with patients of more diverse racial and ethnic background may be different. Medical records rarely reflect every thing that happens during any medical encounter. It is possible that additional testing did occur. However, tests often involve people other than the physician, are billable items in the non-capitated care environment we studied and therefore significant amounts of undocumented testing is unlikely. The use of medical records did allow the date of the incident diagnosis to be pinpointed and allowed us to assess diagnostic evaluation in temporal relation to the incident diagnosis making comparison with diagnostic guidelines possible. Our limited sample size may not have been sufficient to allow accurate assessment of missed GI malignancies.

Conclusion
Community based evaluation of IBS differs from the consensus based guidelines developed by specialists. The limited testing done in this population appeared to limit health care expenditures without adversely impacting the recognition of life threatening GI disease. To allow physician assessment of the potential applicability of published guidelines, the guidelines should always be accompanied by information regarding the target population (i.e. primary care patients versus specialty care patients) and the evidence basis of the guidelines.


References
Lynn, RB & Friedman, LS: Irritable bowel syndrome. N Engl J Med 1993, 329:194045.[PubMed][Full Text]

Maxwell, PR, Mendall, MA, & Kumar, D: Irritable bowel syndrome. Lancet 1997, 350:169195.[PubMed][Full Text]

American Gastroenterological Association Medical Position Statement.: Irritable Bowel Syndrome. Gastroenterology 1997, 112:21182137.[PubMed]

Manning, AP, Thomson, P, Heaton, KW, et al. : Toward positive diagnosis of the irritable bowel BMJ 1978, ii:653654.

Talley, NJ, Phillips, SF, Melton, LJ, III, et al. : Diagnostic value of the Manning criteria in irritable bowel syndrome Gut 1990, 31:7781.[PubMed]

Vanner, SJ, Depew, WT, Paterson, WG, et al. : Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome Am J Gastroenterol 1999, 94:29127.[PubMed][Full Text]

Beck, E & Hurwitz, B: Irritable bowel syndrome Occas Pap R Coll Gen Pract 1992, 58:3235.[PubMed]

Everhart, JE & Renault, PF: Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991, 100:9981005.[PubMed]

Harvey, RF, Salih, SY, & Read, AE: Organic and functional disorders in 2000 gastroenterology outpatients Lancet 1983, i:632634.[PubMed]

Thompson, WG: Irritable bowel syndrome: a management strategy. Bailliere's Clin Gastroenterology 1999, Pages:453460.

Melton, LJ, III: History of the Rochester Epidemiology Project. Mayo Clin Proc 1996, 71:266274.[PubMed]

Kurland, LT & Molgaard, CA: The patient record in epidemiology. Scientific American 1981, 245:5463.[PubMed]

Mark, DH: Race and the Limits of Administrative Data (editorial) JAMA 2001, 285:33738.[PubMed][Full Text]

Yawn, BP, Yawn, RA, Geier, GR, et al. : The impact of requiring patient authorization for use of data in medical records research. J Fam Pract 1998, 47:361365.[PubMed]

Shaneyfelt, TM, Mayo-Smith, MF, & Rothwangle J, J: Are Guidelines Following Guidelines? The Methodological Quality of Clinical Practice Guidelines in the Peer-Reviewed Medical Literature. JAMA 1999, 281:19001905.[PubMed][Full Text]

Harvey, RF, Mauad, EC, & Brown, AM: Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet 1987, i:963965.[PubMed]

Suarez-Almazor, ME, Belseck, E, Russell, AS, & Mackel, JV: Use of lumbar radiographs for the early diagnosis of low back pain. Proposed guidelines would increase utilization. JAMA 1997, 277:17826.[PubMed]

Thompson, WG, Heaton, KW, Smyth, GT, et al. : Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000, 46:7882.[PubMed][Full Text]

U.S. Preventive Services Task Force.: Guide to Clinical Preventive Services 2nd ed. Alexandria, VA: International Medical Publishing 1996, xxlii, 519:521529.

Helm, JF & Sandler, RS: Colorectal cancer screening. Medical Clinics of North America 1999, 83:140322.[PubMed]

Bertram S, S, Kurland, M, Lydick, E, Locke, GR, III, & Yawn, BP: The Patient's Perspective of Irritable Bowel Syndrome. JFP 2001, 50:521525.

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=59674

--------------------
Heather is the Administrator of the IBS Message Boards. She is the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Print     Remind Me     Notify Moderator    

Pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | (show all)

Extra information
0 registered and 14 anonymous users are browsing this forum.

Moderator:  Heather 

Print Thread

Permissions
      You cannot post until you login
      You cannot reply until you login
      HTML is enabled
      UBBCode is enabled

Thread views: 1770979

Jump to

| Privacy statement Help for IBS Home

*
UBB.threads™ 6.2


HelpForIBS.com BBB Business Review